Navigating chemotherapy-induced thrombocytopenia: Insights from the RECITE Phase III trial

Chemotherapy-induced thrombocytopenia (CIT) often forces clinicians to delay or reduce cancer treatment. Recently reported data from the Phase III RECITE trial have demonstrated that romiplostim, a thrombopoietin receptor agonist, can help keep gastrointestinal cancer chemotherapy on course when patients are experiencing CIT. In this interview, Gerald Soff (Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, FL, USA) shares practical strategies for managing CIT in real-world clinical settings. Can you explain how CIT impacts treatment decisions for patients with gastrointestinal cancers? The major adverse impact of CIT in patients with gastrointestinal cancers is the need...